Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of a Blue Light Filtering IOL

This study has been completed.
Information provided by:
Showa University Identifier:
First received: December 11, 2007
Last updated: NA
Last verified: December 2007
History: No changes posted

To compare the effect on blood retinal barrier disruption 3 and 12 months after implantation of either a blue light filtering intraocular lens(blue-filtering IOL) or an ultraviolet light filtering intraocular lens(UV-filtering IOL).

Condition Intervention
to Compare the Effect of Two Types of IOLs
on the Incidence of Cystoid Macular Edema
After Cataract Surgery
Procedure: intraocular lens implantation

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: The Effect of a Blue Light Filtering Intraocular Lens on Blood Retinal Barrier After Cataract Surgery

Resource links provided by NLM:

Further study details as provided by Showa University:

Primary Outcome Measures:
  • To measure FA, VEP and OCT. [ Time Frame: At 3 and 12 months after IOL implantation ] [ Designated as safety issue: Yes ]

Enrollment: 50
Study Start Date: February 2003
Study Completion Date: March 2005
Arms Assigned Interventions
No Intervention: letter
a blue-filtering IOL an UV-filtering IOL
Procedure: intraocular lens implantation
Intraocular lens implantation
Other Names:
  • a blue-filtering IOL (ENV-13, Menicon Co.Ltd, Japan)
  • an UV-filtering IOL (ES-13, Menicon Co.Ltd, Japan)

Detailed Description:

The following parameters were measured for evaluation of blood retinal barrier disruption.

  • the incidence of macular leakage by fluorescence angiography (FA)
  • the mean fluorescein concentration in the vitreous by fluorophotometry (VFP)
  • the thickness of the macula by optical coherence tomography (OCT)


  • the incidence fo macular leakage decreased significantly from 24%(3 months) to 5% (12 months) in the blue-filtering IOL group (P<0.05), and was significantly lower compared with the UV-filtering IOL group at 12 months.
  • the VFP significantly decreased in both group from 3 to 12 months.
  • the OCT decreased from 175 (3 months) to 166 um (12 months) in the blue- filtering IOL group.

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • cataract patients
  • All eligible for intraocular lens implantation

Exclusion Criteria:

  • Patients had undergone an intraocular operation
  • Patients had hypertensive retinopathy
  • Patients had diabetic retinopathy
  • Patients had ange-related macular degeneration
  • no observable fundus
  • The cataract operation was more than 30 minutes in duration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00571831

Showa University Hospital
Tokyo, Japan, 142-8666
Sponsors and Collaborators
Showa University
Study Director: Ryohei Koide, MD, PhD Department of Ophthalmology, School of Medicine, Showa University
  More Information

No publications provided

Responsible Party: Toshihiko Ueda/Associate Professor, Dept. of Ophthalmology, School of Medicine, Showa University Identifier: NCT00571831     History of Changes
Other Study ID Numbers: Toshi-1, showa-IRB-02503
Study First Received: December 11, 2007
Last Updated: December 11, 2007
Health Authority: Japan: Institutional Review Board

Keywords provided by Showa University:
macula edema
intraocular lens
prospective randomized parallel clinical design

Additional relevant MeSH terms:
Capsule Opacification
Macular Edema
Eye Diseases
Lens Diseases
Macular Degeneration
Retinal Degeneration
Retinal Diseases processed this record on November 20, 2014